Stroke in women - oral contraception, pregnancy, and hormone replacement therapy

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 58-73

  Rantanen, Kirsi ^a   Tatlisumak, Turgut ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Hormonal replacement therapy; Oral contraception; Pregnancy; Stroke; Women

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; CYPROTERONE; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; FIBRINOGEN; GESTAGEN; GESTODENE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL; UNINDEXED DRUG; VON WILLEBRAND FACTOR; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ECLAMPSIA; FEMALE; FOLLOW UP; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); MIGRAINE; PARADOXICAL EMBOLISM; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PUERPERIUM; RANDOMISED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE AGGREGATION; THROMBOPHILIA; VASCULAR AMYLOIDOSIS; VASCULITIS; VENOUS THROMBOEMBOLISM;

EID: 84873245024     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547638     Document Type: Review

References (171)

1. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006; 37: 345-50.
2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
3. Towfighi A, Saver JL, Engelhardt R, Ovbiagele B. A midlife stroke surge among women in the United States. Neurology 2007; 69: 1898-904.
4. Putaala J, Metso AJ, Metso TM, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke. Stroke 2009; 40: 1195-203.
5. Bushnell CD, Hurn P, Colton C, et al. Advancing the study of stroke in women. Summary and recommendations for future research from an NINDs-sponsored multidisciplinary working group. Stroke 2006; 37: 2387-99.
6. Lewis MA. The epidemiology of oral contraceptives use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179: 1086-97.
7. Chandra AMG, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 2005; 23: 19-21.
8. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: I-VII, 1-89.
9. Lorentz IT. Parietal lesion and Enovid. BMJ 1962; 2: 1191.
10. Inman WHW, Vessey MP. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of childbearing age. BMJ 1968; 2: 193-9.
11. Vessey MP, Doll R. Investigation of the relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; 2: 199-205.
12. Junod SW, Marks L. The approval of the first oral contraceptive pill in the United States. J Hist Med Allied Sci 2002; 57: 117-60.
13. Shufelt CL, Bairey-Merz CN. Contraceptive hormone use and the cardiovascular disease. JACC 2009; 53: 221-31.
14. Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ 2009; 339: b2895.
15. Roell A, Schueller P, Schulz A, et al. Effect of oral contraceptives and and ovarian cycle on platelet function. Platelets 2007; 18: 165-70.
16. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
17. Endrikat J, Klipping C, Cronin M, et al. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 mcg of ethinyl estradiol and 100 mcg of levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002; 65: 215-21.
18. Chasan-Taber L, Stampfer M. Oral contraceptives and myocardial infarction-the search for smoking gun. N Engl J Med 2001; 345: 1841-2.
19. Suthipongse W, Taneepanichskul S. An open-label randomized study of oral contraceptives between medications containing 3mg of drospirenone/30 mcg ethinyl estradiol and 150 mcg levonorgestrel/30 mcg ethinyl estradiol in Thai women. Contraception 2004; 69: 23-6.
20. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997; 59: 237-43.
21. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of new oral contraceptives containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-21.
22. Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Coronary Artery Risk Development in Young Adults. Diabetes Care 2002; 25: 1027-32.
23. Bairey-Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenomia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE-study. J Am Coll Cardiol 2003; 41: 413-9.
24. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87: 2013-7.
25. Snell-Bergeon JK, Dabelea D, Ogden LG, et al. Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2142-8.
26. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-7.
27. Chandra AMG, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 2005; 23: 19-21.
28. Lidegaard Q, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A five-year national case-control study. Contraception 2002; 65: 187-96.
29. World Health Organization Collaborative Study of Cardiovascular disease and steroid hormone contraseption. Venous thromboembolic disease and combined oral contraceptives: results of international multi-centre case-control study. Lancet 1995; 346: 1575-82.
30. Lidegaar Q, Lokkegaard E, Svendsen A-L, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
31. van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
32. Van Vlijmen E, Brouwer J, Veeger N, EskesT, de Graeff P, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch Intern Med 2007; 167: 282-9.
33. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives. An approach to specifying rates. Eur J Epidemiol 2005; 20: 509-16.
34. Eichjinger S. Consequences of thrombophilia screening for life quality in women before prescription of oral contraceptives and family members of VTE patients. Hämostaseologie 2001; 1: 110-1.
35. Blanco-Molina A, Monreal M. Venous thromboembolism in women taking hormonal contraceptives. Expert Rev Cardiovasc Ther 2010; 8; 211-5.
36. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-8.
37. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-70.
38. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a metaanalysis. Blood 2006; 107: 2766-73.
39. Coutinho JM, Ferro JM, Canhao P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40: 2356-61.
40. Vandenbroucke JP, Koster T, Briet T, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
41. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.
42. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and homeostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95: 193-7.
43. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 9: 465-70.
44. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
45. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-57.
46. Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122: 471-8.
47. Frederiksen J, Juul K, Grande P, et al. Methylene-tetrahydro-folate reductase polymorphism (C677T), hyperhomocystenemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from Copenhagen City Heart Study. Blood 2004; 104: 3046-51.
48. Roldan V, Lecumberri R, Munoz-Torrero JF, et al. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2009; 124: 174-7.
49. Pruissen DMO, Slooter AJC, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral, and risk of ischemic stroke. Blood 2008; 111: 1282-6.
50. Slooter AJC, Rosendaal FR, Tanis BC, Kemmeren JM, van den Graaf Y. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005; 3: 1213-7.
51. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives. A meta-analysis. JAMA 2000; 284: 72-8.
52. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1313-7.
53. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease. Obstet Gynecol 1985; 66: 1-4.
54. Hirvonen E, Idänpään-Heikkilä J. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol 1990; 163: 281-4.
55. Chang KK, Chow LP, Rider RV. Oral contraceptives and stroke: a preliminary report on an epidemiologic study in Taiwan, China. Int J Gynecol Obstet 1986; 24: 421-30.
56. Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives. A critical evaluation of the evidence. Arch Intern Med 2004; 164: 741-7.
57. Baillargeon J-P, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 3863-70.
58. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reproduc 2002; 17: 2307-14.
59. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003; 68: 11-7.
60. Yang L, Kuper H, Sandin S, et al. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke 2009; 40: 1050-8.
61. Curtis K, Mohllajee A, Martin S, et al. Combined oral contraceptive use among women with hypertension. Contraception 2006; 73: 179-88.
62. Siritho S, Thrift AG, Mcneil JJ, et al. Risk of ischemic stroke among users of the oral contraceptive pill. The Melbourne Risk Factor Study (MERFS) Group. Stroke 2003; 34: 1575-80.
63. Chang C, Donaghy M, Poulter N. Migraine and stroke in young women: a case-control study. BMJ 1999; 318: 13-8.
64. Gillmer MD. The pill: an historical overview. In: Hannaford PC, Webb AMC, eds. Evidence-guided prescribing of the Pill. Cahnforth, Lancashire, England: Parthenon publishing, 1996.
65. World Health Organization collaborative study of cardiovascular disease and use of oral and injectable-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-24.
66. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke. A meta-analysis. Stroke 2009; 40: 1059-62.
67. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transienbt ischemic attack. Stroke 2006; 37: 577-617.
68. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
69. Department of Health, Scottish Executive Health Department, and Department of Health, Social Services and Public Safety, Northern Ireland. Why mothers die. Sixth report of confidential enquiries into maternal deaths in the United Kingdom, 2000-2002. London. RCOG Press, 2004.
70. Simolke GA, Cox SA, Cunningham FG. Cerebrovascular accidents complicating pregnancy and the puerperium. Obstet Gynecol 1991; 78: 27-42.
71. Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375: 1609-23.
72. van Oppen ACC, van der Tweel L, Alsbach GBJ, Heethaar RM, Bruinse HW. A longitudinal study of maternal hemodynamics during normal pregnancy. Obstet. Gynecol 1196; 88: 40-6.
73. Bogousslavsky J, Pierre P. Ischaemic stroke in patients under age 45. Neurol Clin 1992; 10: 113-24.
74. Lidegaard O, Soe M, Andersen MVN. Cerebral thromboembolism among young women and men in Denmark 1977-1982. Stroke 1985; 17: 670-5.
75. Petiti DB, Sidney S, Quesenberry CP, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28: 280-3.
76. Davie CA, ÓBrien P. Stroke and pregnancy. J Neurol Neurosurg Psychiatry 2008; 79: 240-5.
77. Jaigobin C, Silver FL. Stroke and pregnancy. Stroke 2000; 31: 2948-51.
78. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106: 509-16.
79. Bateman BT, Schumacher HC, Bushnell CD, et al. Intracerebral hemorrhage in pregnancy. Neurology 2006; 67: 424-9.
80. Jeng JS, Tang SC, Yip PK. Incidence and etiologies of stroke during pregnancy and puerperium as evidenced in Taiwanese women. Cerebrovasc Dis 2004; 18: 290-5.
81. Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline. BMJ 2005; 330: 576-80.
82. Sharshar T, Lamy C, Mas JL. Incidence and causes of stroke associated with pregnancy and puerperium: a study in public hospitals of Ile de France. Stroke 1995; 26: 930-6.
83. Kittner SJ, Stern BJ, Feeser BJ, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335: 768-74.
84. Blaauw J, van Pampus M, van Doormaal J. Increased intima-media thickness after early-onset preeclampsia. Obstet Gynecol 2006; 107: 1345-51.
85. Isler CM, Rinehart BK, Terrone DA, et al. Maternal mortality associated with HELLP. Am J Obstet Gynecol 1999; 181: 924-8.
86. Bushnell CD. Stroke in Women: Risk and prevention throughout the lifespan. Neurol Clin 2008; 26: 1161-70.
87. Abercrombie J. Pathological and practical researches on diseases of the brain and spinal cord. Edinburgh 1828; 83-5. Cited by: Donaldson JO, ed. Neurology of pregnancy. Philadelphia, PA: WB Saunders, 1978.
88. Srinivasan K. Ischemic cerebrovascular disease in the young: two common causes in India. Stroke 1984; 15: 733-5.
89. Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000; 31: 1274-82.
90. Mehraein S, Ortwein H, Busch M, et al. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry 2003;74:814-816.
91. Ehtisham A, Stern BJ. Cerebral Venous Thrombosis. A review. The Neurologist 2006; 12: 32-8.
92. Calado S, Vale-Santos J, Lima C, Viena-Babtista M. Postpartum cerebral angiopathy: vasospasm, vasculitis, or both? Cerebrovasc Dis 2004; 18: 340-1.
93. Konstantinopoulos PA, Mousa S, Khairallah R, Mitanos G. Postpartum cerebral angiopathy: an important diagnostic consideration in the postpartum period. Am J Obstet Gynecol 2004; 191; 375-7.
94. Treadwell SD, Thanvi B, Robinson TG. Stroke in pregnancy and the puerperium. Postgrad Med J 2008; 84: 238-45.
95. Barrett JM, Van Hooydonk JE, Boehm FH. Pregnancy-related rupture of arterial aneurysms. Obstet Gynecol Surv 1982; 37: 557-66.
96. Dias K, Sekhar LN. Intracranial hemorrhage from aneurysms and arteriovenous malformations during pregnancy and the puerperium. Neurosurgery 1990; 27: 855-66.
97. Royal College of Physicians. National clinical guidelines for stroke. 2nd edn. London: Intercollegiate Stroke Working Party, RCP, 2004.
98. Horton JC, Chambers WA, Lyons SL, Adams RJ, Kjellberg RN. Pregnancy and the risk of hemorrhage from cerebral arteriovenous malformations. Neurosurgery 1990; 27: 867-72.
99. Daehnert I, Ewert P, Berger F. Echocardiography guided closure of patent foramen ovale during pregnancy in recurrent strokes. J Interv Cardiol 2001; 14: 191-2.
100. Banhidy F, Acs N, Horvath-Puho E, Czeizel A. Pregnancy complications and delivery outcomes in pregnant women with severe migraine. Eur J Obstet Gynecol Reproduct Biol 2007; 134: 157-63.
101. James AH, Jamison M, Biswas M, Brancazio L, Swamy G, Myers E. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006; 113: 1564-71.
102. Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based casecontrol study. BMJ 2009; 338: b664.
103. Ginsberg JS, Brill-Edvards P, Burrows RF, Bona R, Prandoni P and Buller HR. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
104. Elkayam U. Pregnancy and cardiovascular disease. In: Braunwald́s Heart Disease: a Textbook of Cardiovascular Medicine (Seventh Edition). Zipes DP, Libby P, Bonow RO, Braunwald E. Elsevier, PA, USA (2005).
105. Svensson PJ, Dahlback P. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
106. Poort SJ, Rosendaal SR, Reitsma PH, Bertina RM. A genetic variation in the 3́-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
107. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocystinemia: a common mutation in the methylene-tetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
108. Morrison ER, Miedzybrodzka ZH, Campbell DM, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-85.
109. Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program 2009: 233-9.
110. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classifiaction criteria for definite an tiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
111. Tripodi A. Testing for lupus anticoagulants: all that a clinician should know. Lupus 2009; 18: 291-8.
112. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-7.
113. The APASS writing committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
114. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.
115. Bates SM, Greer IM, Pabinger I, Sofaer S, Hirsch J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 844S-886S.
116. Khamashta MA. Management of thrombosis in the antiphospholipid syndrome. Lupus 1996; 5: 463-6.
117. Murugappan A, Coplin WM, Al-Sadat AN, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology 2006; 66: 768-70.
118. Leonhardt G, Gaul C, Nietsch H, Buerke M, Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006; 21: 271-6.
119. Johnson DM, Kramer DC, Cohen E, Rochon M, Rosner M, Weinberger J. Thrombolytic therapy for acute stroke in late pregnancy with intraarterial recombinant tissue plasminogen activator. Stroke 2005; 36: e53-e55.
120. Wiese KM, Talkad A, Mathews M, Wang D. Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke. Stroke 2006; 37: 2168-9.
121. Trukhacheva E, Scharff M, Gardner M, Lakkis N. Massive pulmonary embolism in pregnancy treated with tissue plasminogen activator. Obstet Gynecol 2005; 106: 1156-8.
122. Keyser JD, Gdovinova Z, Uyttenboogaart M, Vroomen PC, Luijckx. Intravenous alteplase for stroke: Beyond the guidelines and in particular clinical situations. Stroke 2007; 38: 2612-8.
123. Holden E, Ranu H, Sheth A. Thrombolysis for massive pulmonary embolism in pregnancy. A report of three cases and follow-up over a two-year period. Thromb Res 2011; 127: 58-9.
124. Mendez JC, Masjuan J, Garcia N, de Lecinana M. Successful intraarterial thrombolysis for acute ischemic stroke in the immediate postpartum period: case report. Cardiovasc Intervent Radiol 2008; 31: 193-5.
125. CLASP: a randomized trial of low-dose aspirin for prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-Dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619-29.
126. Mckenna R, Cole ER, Vasan V. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983; 103: 325-7.
127. Richter C, Sitzmann J, Lang P. Excretion of low-molecular weight heparin in human milk. Br J Clin Pharmacol 2001; 52: 708-10.
128. Greer IA, Nelson-Pierce C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-7.
129. Bates SM, Greer IM, Pabinger I, Sofaer S, Hirsch J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practise Guidelines. Chest 2008;133:844S-886S.
130. Lawlor DA, Emberson JR, Ebrahim S, Whincup PH, Wannamethee SG, Walker M et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study. Circulation 2003; 107: 1260-4.
131. Zhang X, Shuh XO, Gao Y-T, Yang G, Li H, Zheng W. Pregnancy, childrearing, and risk of stroke in Chinese women. Stroke 2009; 40: 2680-4.
132. Wolff B, Volzke H, Robinson D, et al. Relation of parity with common carotid intima-media thickness among women of the study of health in Pomerania. Stroke 2005; 36: 938-43.
133. Skilton MR, Serusclat A, Begg L-M, Moulin P, Bonnet F. Parity and carotid atherosclerosis in men and women: insights into the roles of childbearing and child-rearing. Stroke 2009; 40: 1151-7.
134. Skilton MR, Bonnet F, Begg LM, et al. Childbearing, child-rearing, cardiovascular risk factors, and progression of carotid intima-media thickness. Stroke 2010; 41: 1332-7.
135. Report of the National Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
136. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2008; 2: 249-59.
137. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974.
138. Garovic VD, Bailey GR, Boerwinkle E, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. Hypertension 2010; 28: 826-33.
139. Brown DW, Dueker N, Jamieson DJ, Cole JW, Wozniak MA and Stern BJ. Pre-eclampsia and the risk of ischemic stroke among young women: results from the Stroke Prevention in Young Women Study. Stroke 2006; 37: 1055-6.
140. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and Eric acid: a pathogenetic link? J Am Soc Nephrol 2005; 16: 1909-19.
141. Laughon CK, Catov J, Provins T, Roberts JM, Gandley RE. Elevated first-trimester uric acid concentrations are associated with the development of gestational diabetes. American J of Obstet and Gynecol 2009; 201; 402, e1-5.
142. Laughon SK, Catov J, Powers RW, Roberts JM, Gandley RE. Am J Hypertens 2011; 24: 489-95.
143. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker JP. Preeclampsia is associated with increased risk of stroke in the adult offspring. The Helsinki Birth Cohort Study. Stroke 2009; 40: 1176-80.
144. Lamy C, Hamon JB, Coste J, Mas JL for the French Study Group on Stroke in Pregnancy. Ischemic stroke in young women: Risk of recurrence during subsequent pregnancies. Neurology 2000; 55: 269-7.
145. Keating N, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian AZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern med 1999; 130: 545-53.
146. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 2001; 38: 243-61.
147. Nelson HD, Humphrey LL, Hmcgren P, Teusch SM, Allan JD. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002; 288: 872-81.
148. Viscoli CM, Brass LM, Kernan WN. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-9.
149. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
150. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-84.
151. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288: 49-57.
152. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.
153. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330: 342.
154. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.
155. Lagro-Janssen ALM, Knufing MWA, Schreurs L, van Wheel C. Significant fall in hormone therapy use in general practice. Family Practice 2010; 27: 424-9.
156. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008; 372: 608-10.
157. Fournier A. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? a review. Menopause Int 2010; 16: 23-32.
158. de Vries CS, Bromley SE, Farmer RD. Myocardial infarction risk and hormone replacement: differences between products. Maturitas 2006; 53: 343-50.
159. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Hundrup YA. Increased risk of stroke in hypertensive women using hormone therapy. Arch Neurol 2003; 60: 1379-84.
160. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: The Esther Study. Circulation 2007; 115: 840-5.
161. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N Cohort Study. Arterioscler Thromb Vasc Biol 2010; 30: 340-5.
162. Renoux C, DelĺAniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested casecontrol study. BMJ 2010; 340: c2519.
163. Daly E, Vessey MP, Hawkins MM. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
164. Perez G, Garcia Rodriguez LA, Castellague J, Dugue Oliart A. Hormone replacement therapy and risk of venous thromboembolism:population based case-control study. Br Med J 1997; 314: 796-800.
165. Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. European Heart Journal 2008; 29: 2031-41.
166. Harmon S, Brinton E, Cedars M, Lobo RA, Manson JE and Merriam G. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-1.
167. Wolff B, Volzke H, Robinson D, et al. Relation of parity with common carotid intima-media thickness among women of the study of health in Pomerania. Stroke 2005; 36: 938-43.
168. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e71.
169. Niewada M, Kobayashi A, Sandercock PA, Kaminski P, Czlonkowska A. Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischemic stroke in the international stroke trial. Neuroepidemiology 2005; 24: 123-8.
170. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age at natural menopause and risk of ischemic stroke. The Framingham Heart Study. Stroke 2009; 40: 1044-9.
171. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265-79.